PARP Inhibitor Combinations in First Line mCRPC: A Systematic Review and Meta-Analysis.

Rashid K Sayyid Zachary KlaassenAlejandro BerlinSoumyajit RoyLeonardo R BrandãoRui BernardinoJulian ChavarriagaDi Maria JiangDaniel E SprattNeil E FleshnerChristopher J D Wallis

Published in: BJU international (2023)

PARPi addition to ARATs in the first-line mCRPC setting is associated with rPFS benefits across subgroups, with the greatest magnitude of benefit in BRCA1/2-mutated patients. OS benefits remain inconsistent irrespective of HRRm status, with significant increases in grade≥3 TEAEs, particularly anemia. Currently, we suggest this combination approach be selectively offered to HRRm patients, preferentially BRCA1/2-mutated.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis